1. Home
  2. XEL vs INSM Comparison

XEL vs INSM Comparison

Compare XEL & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Xcel Energy Inc.

XEL

Xcel Energy Inc.

HOLD

Current Price

$74.44

Market Cap

47.5B

Sector

Utilities

ML Signal

HOLD

Logo Insmed Incorporated

INSM

Insmed Incorporated

HOLD

Current Price

$178.04

Market Cap

41.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XEL
INSM
Founded
1909
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Power Generation
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
47.5B
41.2B
IPO Year
N/A
2000

Fundamental Metrics

Financial Performance
Metric
XEL
INSM
Price
$74.44
$178.04
Analyst Decision
Buy
Strong Buy
Analyst Count
14
21
Target Price
$84.00
$185.84
AVG Volume (30 Days)
5.6M
3.7M
Earning Date
02-05-2026
10-30-2025
Dividend Yield
3.08%
N/A
EPS Growth
N/A
N/A
EPS
3.27
N/A
Revenue
$14,228,000,000.00
$447,022,000.00
Revenue This Year
$13.16
$43.10
Revenue Next Year
$7.63
$128.25
P/E Ratio
$22.68
N/A
Revenue Growth
3.38
30.34
52 Week Low
$62.58
$60.40
52 Week High
$83.01
$212.75

Technical Indicators

Market Signals
Indicator
XEL
INSM
Relative Strength Index (RSI) 38.96 40.56
Support Level $72.54 $172.65
Resistance Level $74.29 $179.33
Average True Range (ATR) 1.27 7.15
MACD 0.00 -3.04
Stochastic Oscillator 39.51 37.18

Price Performance

Historical Comparison
XEL
INSM

About XEL Xcel Energy Inc.

Xcel Energy manages utilities serving 3.8 million electric customers and 2.2 million natural gas customers in eight states. Its utilities are Northern States Power, which serves customers in Minnesota, North Dakota, South Dakota, Wisconsin, and Michigan; Public Service Company of Colorado; and Southwestern Public Service Company, which serves customers in Texas and New Mexico. It is one of the largest renewable energy suppliers in the US, with more than half of its electricity sales coming from carbon-free energy.

About INSM Insmed Incorporated

Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.

Share on Social Networks: